APR Applied Pharma Research (RLF.SW)

Executive Summary

APR Applied Pharma Research is a Swiss specialty pharmaceutical company that leverages proprietary drug delivery technologies to develop and commercialize treatments for rare and ultra-rare diseases. As a wholly-owned subsidiary of Relief Therapeutics Holding AG (SIX: RLF), APR benefits from integrated R&D and manufacturing capabilities. The company's portfolio includes approved products addressing unmet medical needs, and it continues to advance its pipeline through innovative formulation expertise and a focused commercial strategy in niche therapeutic areas. With a strong foundation in drug delivery, APR is positioned to deliver growth through both organic pipeline progression and strategic partnerships.

Upcoming Catalysts (preview)

• Q4 2026FDA decision on New Drug Application for lead rare disease candidate65% success
• Q2 2027Top-line results from Phase 2 trial in ultra-rare metabolic disorder75% success
• Q3 2026Announcement of commercialization partnership for European markets50% success